REVOLADE (eltrombopag) - Risk of Severe Hepatotoxicity
Issued August 25, 2016
Issue
A recent review of all clinical trial and post-marketing cases identified five (5) cases fulfilling Hy’s law criteria (severe drug-induced liver injury).
Hazard description
Product safety
Get notified of similar recallsEnter your email to receive alerts when new recalls are issued by the same agency.
Subscribed. You'll get an email when new recalls are issued.
RecallTracker